In addition, this study revealed that the elevated expression of IDO1 in BRAF V600E-mutant CRC is accompanied by increased expression of other immune checkpoints (e.g., LAG3), offering insights for developing novel combination therapy strategies. This evidence concerns the gene BRAF and colorectal carcinoma.